• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Determination of finasteride in human plasma by HPLC-MS].

作者信息

Li Xiang-yang, Ding Li, Li Li-min, Hao Xin-yu, Zhang Zheng-xing

机构信息

Department of Pharmacology, Qinghai Medical College, Xining 810001, China.

出版信息

Yao Xue Xue Bao. 2003 Jun;38(6):455-7.

PMID:14513808
Abstract

AIM

To develop an HPLC-MS assay for determination of finasteride in human plasma and to investigate the bioequivalence in healthy volunteers.

METHODS

After alkalization with sodium hydroxide, plasma was extracted with ethyl acetate and separated using a C18 column with a mobile phase of methanol-water (85:15). LC-ESI-MS was performed in the selected ion monitoring (SIM) mode using target ions at m/z 395 for finasteride and m/z 407 for the IS. The fragmentor voltage was 120 V. A randomized crossover design was performed in 20 healthy volunteers. In the two study periods, a single 10 mg dose of each tablet was administered to each volunteer.

RESULTS

Calibration curves were linear over the range 1-200 micrograms.L-1 (r = 0.9986). The limit of determination for finasteride in plasma was 0.05 microgram.L-1. The recovery of finasteride from plasma was in the range of 85.9%-98.7%. The results of variance analysis and two one-side t-test showed that there was no significant difference between the two formulations in the AUC and Cmax.

CONCLUSION

The assay was proved to be sensitive, accurate and convenient. The two formulations were bioequivalent.

摘要

相似文献

1
[Determination of finasteride in human plasma by HPLC-MS].
Yao Xue Xue Bao. 2003 Jun;38(6):455-7.
2
[Pharmacokinetics and bioequivalence of trimebutine dispersive tablet in healthy subjects].曲美布汀分散片在健康受试者中的药代动力学及生物等效性
Yao Xue Xue Bao. 2004 Mar;39(3):208-11.
3
[Pharmacokinetics and bioequivalence of eperisone hydrochloride tablet in healthy subjects].盐酸乙哌立松片在健康受试者中的药代动力学与生物等效性
Yao Xue Xue Bao. 2004 Apr;39(4):309-11.
4
Bioequivalence study of finasteride. Determination in human plasma by high-pressure liquid chromatography coupled to tandem mass spectrometry.非那雄胺的生物等效性研究。采用高压液相色谱-串联质谱法测定人血浆中的非那雄胺。
Arzneimittelforschung. 2001 Feb;51(2):145-50. doi: 10.1055/s-0031-1300016.
5
A rapid, simple, specific liquid chromatographic-electrospray mass spectrometry method for the determination of finasteride in human plasma and its application to pharmacokinetic study.一种快速、简便、特异的液相色谱-电喷雾质谱法用于测定人血浆中非那雄胺及其在药代动力学研究中的应用。
J Pharm Biomed Anal. 2007 Mar 12;43(4):1507-13. doi: 10.1016/j.jpba.2006.10.024. Epub 2006 Nov 21.
6
Determination of glycyrrhetic acid in human plasma by LC-ESI-MS.采用液相色谱-电喷雾电离质谱法测定人血浆中甘草次酸的含量。
J Pharm Biomed Anal. 2006 Feb 24;40(3):758-62. doi: 10.1016/j.jpba.2005.10.047. Epub 2005 Dec 7.
7
Determination of mianserin in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-ESI/MS): application to a bioequivalence study in Chinese volunteers.高效液相色谱-电喷雾电离质谱法(HPLC-ESI/MS)测定人血浆中的米安色林:在中国志愿者中的生物等效性研究应用
J Pharm Biomed Anal. 2008 Aug 5;47(4-5):994-9. doi: 10.1016/j.jpba.2008.04.015. Epub 2008 Apr 23.
8
Determination of tegaserod by LC-ESI-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers.用液相色谱-电喷雾串联质谱法测定替加色罗及其在健康中国志愿者体内的药代动力学研究中的应用。
J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jan 1;861(1):151-7. doi: 10.1016/j.jchromb.2007.11.011. Epub 2007 Nov 19.
9
[Determination of dextrorphan in human plasma and pharmacokinetic study].[人血浆中右啡烷的测定及药代动力学研究]
Yao Xue Xue Bao. 2004 Jun;39(6):449-52.
10
Determination of glycyrrhetic acid in human plasma by HPLC-MS method and investigation of its pharmacokinetics.采用高效液相色谱-质谱法测定人血浆中甘草次酸及其药代动力学研究。
J Clin Pharm Ther. 2008 Jun;33(3):289-94. doi: 10.1111/j.1365-2710.2008.00899.x.